Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20(+) B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Cota Stirner, Mariana, Kilavuz, Nurgul, Chiu, Christopher, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Ahmadi, Tahamtan, Hutchings, Martin, Lugtenburg, Pieternella J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115554/
https://www.ncbi.nlm.nih.gov/pubmed/36548927
http://dx.doi.org/10.1200/JCO.22.01725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115554/
https://www.ncbi.nlm.nih.gov/pubmed/36548927
http://dx.doi.org/10.1200/JCO.22.01725

Ejemplares similares